Methods and Compositions of Matter for Activating Class I Histone Deacetylases (HDACs) for Treatment of Human Disease

The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).

Researchers

Li-Huei Tsai / Stephen Haggarty / Ling Pan / Debasis Patnaik

Departments: DLC Heads Science
Technology Areas: Therapeutics: Small Molecules
Impact Areas: Healthy Living

  • activators of class i histone deacetlyases (hdacs) and uses thereof
    United States of America | Granted | 9,115,053
  • activators of class i histone deacetlyases (hdacs) and uses thereof
    United States of America | Granted | 10,167,277
  • activators of class i histone deacetylases (hdacs) and uses thereof
    United States of America | Granted | 11,084,803

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.